Skip to Main Content

Skip Nav Destination

Issues

Select Year

Issue

In this Issue

New Molecular Targets
Handling of Toxicities Related to Targeted Therapies
Telomerase‐Targeting Agents
Target Identification and Validation
Therapeutic Agents - Small Molecule Kinase Inhibitors
Molecular Classification of Tumors
Pediatric-Early Drug Development
Topoisomerase Inhibitors
Heat Shock Proteins
Chemistry
Differentiation
Monoclonal Antibodies
Tumor Suppressors
Cellular Responses to Therapy
Biomarkers
Tubulin‐interacting Agents
Metastasis and Invasion
Apoptosis, Necrosis, and Autophagy
Angiogenesis and Antiangiogenesis Agents
mTOR / PI3‐Kinase
The Cancer Genome
DNA Repair and Modulation
In vitro and in vivo Models for Targets
Pharmacogenetics, Pharmacogenomics, and Therapeutic Response
Chemoprevention
RNA and RNA‐Based Technologies and Therapies
Predictive Biomarkers - Challenges in Measuring and Using the Targets
Other Therapeutic Agents
Clinical Trials
Tumor Immunology Targets
The Cancer Epigenome
In vivo Imaging of Drug Responses
Miscellaneous Topics
Targeting the Tumor Microenvironment
EGFR/Her2
Cancer Stem Cells
Gene Therapies
Genomics, Proteomics, and Target Discovery
Novel Assay Technology
Drug Metabolism, Transport, and Biodistribution
Proof of Concept Clinical Trial Design
Protein‐Protein Interaction
Radiotherapeutics
Drug Screening
Drug Delivery
Drug Design
Pharmacokinetics and Pharmacodynamics
Emerging Targets in Cancer Prevention
Metabolism
Monoclonal Antibodies Therapies
Imaging
Natural Products
Cell Cycle Regulators
Toxicology
Signal Transduction Modulators
Animal Models
Tumor Microenvironment
Epigenetic Targets
Therapeutic Agents - Biological
MAPK Pathways
Drug Resistance and Modifiers
Hormonal Agents and Therapy
Topoisomerase I and II Alpha‐Specific Inhibitors
Drug Responses in Genetically‐Engineered Mouse Models for Cancer
Targeting the PI3K Pathway
Bioinformatics
Circulating Tumor Cells and Tumor Dormancy

Search within issue:

Search within issue

Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA

New Molecular Targets

Handling of Toxicities Related to Targeted Therapies

Telomerase‐Targeting Agents

Target Identification and Validation

Therapeutic Agents - Small Molecule Kinase Inhibitors

Molecular Classification of Tumors

Pediatric-Early Drug Development

Topoisomerase Inhibitors

Heat Shock Proteins

Chemistry

Differentiation

Monoclonal Antibodies

Tumor Suppressors

Cellular Responses to Therapy

Biomarkers

Tubulin‐interacting Agents

Metastasis and Invasion

Apoptosis, Necrosis, and Autophagy

Angiogenesis and Antiangiogenesis Agents

mTOR / PI3‐Kinase

The Cancer Genome

DNA Repair and Modulation

In vitro and in vivo Models for Targets

Pharmacogenetics, Pharmacogenomics, and Therapeutic Response

Chemoprevention

RNA and RNA‐Based Technologies and Therapies

Predictive Biomarkers - Challenges in Measuring and Using the Targets

Other Therapeutic Agents

Clinical Trials

Tumor Immunology Targets

The Cancer Epigenome

In vivo Imaging of Drug Responses

Miscellaneous Topics

Targeting the Tumor Microenvironment

EGFR/Her2

Cancer Stem Cells

Gene Therapies

Genomics, Proteomics, and Target Discovery

Novel Assay Technology

Drug Metabolism, Transport, and Biodistribution

Proof of Concept Clinical Trial Design

Protein‐Protein Interaction

Radiotherapeutics

Drug Screening

Drug Delivery

Drug Design

Pharmacokinetics and Pharmacodynamics

Emerging Targets in Cancer Prevention

Metabolism

Monoclonal Antibodies Therapies

Imaging

Natural Products

Cell Cycle Regulators

Toxicology

Signal Transduction Modulators

Animal Models

Tumor Microenvironment

Epigenetic Targets

Therapeutic Agents - Biological

MAPK Pathways

Drug Resistance and Modifiers

Hormonal Agents and Therapy

Topoisomerase I and II Alpha‐Specific Inhibitors

Drug Responses in Genetically‐Engineered Mouse Models for Cancer

Targeting the PI3K Pathway

Bioinformatics

Circulating Tumor Cells and Tumor Dormancy